Cellular coenzyme · Fact sheet

NAD+

Also known as nicotinamide adenine dinucleotide · NAD

NAD+ is a cellular coenzyme, distinct from the precursors NR and NMN. The selected human pilot measured metabolites, not wellness benefits. The linked FDA warning concerns compounded-product risks and does not establish an approved wellness indication.

Status unclear or variableLimited or unclear evidence

What is NAD+?

NAD+ is a coenzyme found in every living cell. It participates in energy metabolism, redox reactions, DNA-repair signaling, and enzymes such as sirtuins.

NAD+ itself is distinct from precursors such as nicotinamide riboside and nicotinamide mononucleotide. Raising a blood biomarker with a precursor is also different from proving a meaningful health outcome.

Benefits & claims

NAD+ biology intersects with metabolism, mitochondrial function, DNA repair, inflammation, and aging research.

Commercial infusion programs often move from that mechanism to broad benefit claims faster than controlled human evidence allows.

What the evidence supports

  • A small infusion study described changes in circulating NAD-related metabolites but did not establish a clinical benefit.
  • NAD precursors often increase NAD-related biomarkers in human trials; benefits in physical, cognitive, or metabolic outcomes are inconsistent and cannot be assigned to NAD+ infusions.
Research areas
  • Cellular energy and redox biology
  • Aging-related biomarker changes
  • Metabolic and neurodegenerative conditions
  • Commercial infusion tolerability

Dosage & frequency

Human study context

A small intravenous pilot measured NAD-related metabolites. It did not establish a repeated infusion schedule or a clinical anti-aging benefit.

Exploratory intravenous metabolomics pilot

Eight healthy men received NAD+; three received saline

Amount
750 mg
Frequency
One six-hour infusion
Route studied or labeled
Intravenous

Small metabolism study without established anti-aging efficacy.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • NAD+, nicotinamide riboside, and NMN are different molecules and cannot share a dose by inference.

Interactions & precautions

  • FDA warns about adverse events from unsuitable ingredients used in sterile NAD+ compounding.

What is still unresolved

  • Clinical efficacy, repeated-infusion safety, useful frequency, and a validated human half-life remain unresolved.

Side effects & risks

  • FDA has received adverse-event reports involving compounded NAD+ products, including severe chills, shaking, vomiting, and fatigue, and has warned about unsuitable ingredients used in sterile compounding.
  • A retrospective commercial-clinic study reported frequent gastrointestinal symptoms and changes in heart rate or chest pressure during NAD+ infusions; it did not establish efficacy.
  • Compounded sterile products can introduce contamination, potency, and quality risks that are separate from the molecule's theoretical biology.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

Human studies can describe pharmacokinetics or short-term laboratory changes, but controlled evidence for patient-centered benefits from NAD+ itself is missing. Reviews of NAD-boosting interventions find more biomarker evidence than reproducible functional benefit.

Studies

What do the human studies show?

Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.

Who took part, what was measured, and what the study found
Study and peopleQuestion and follow-upResult and limits
NAD+ metabolome pilot

Human infusion cohort; full participant details not extracted

Participant count not confirmed in this summary

Pilot pharmacokinetic study; human

NAD+ versus Not extracted

Six-hour exposure with short-term sampling

Primary: Plasma and urine NAD-related metabolites

Phase: Not listed in this summary
Registry status: Not assessed
Registry results: Not assessed
Publication: published; peer reviewed

The report describes metabolite handling during and after exposure.

Cannot tell us: Does not measure longevity, addiction recovery, cognition or durable functional benefit. Sample size and full risk assessment are not extracted.

Safety, uncertainty, and source details

See primary paper; absence of a signal in this study does not establish general safety.

Limited to the studied population, formulation and follow-up.

Funding/conflicts: Not confirmed in this summary; check the full paper.

Source checked: 2026-09-18. Independent clinical review: not completed.

What these results can and cannot tell us

Does the NAD+ pilot demonstrate a wellness benefit?

The pilot documents short-term metabolite handling.

Limit: It does not demonstrate improved cognition, recovery or longevity. NR and NMN results cannot be transferred to NAD+.

Check the sources: NAD+ plasma and urine metabolome pilot (checked 2026-09-18) · FDA sterile compounding ingredient warning (checked 2026-09-18)

What is approved, and for whom?

United States records selected for the questions above; not a complete label or a worldwide approval inventory.

NAD+: Wellness and aging

Compounded products; formulation varies · Wellness populations

search incomplete — The linked FDA warning documents compounding risks, not an approved indication. This page has not completed an exhaustive Drugs@FDA ingredient/alias search.

Exact linked source and stated indication only; not an exhaustive regulatory search.

Read the original source · Source checked: 2026-09-18

Related, not equivalent: Nicotinamide riboside · Nicotinamide mononucleotide.

Compare research questions · Submit a source-based correction

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Positive account · personal report

More energy during several combined exposures

A commenter reported more energy after experiences with SS-31, MOTS-c and NAD+, following an earlier period of low energy.

Reported use in this account

Product
Product described as NAD+
Amount
100 mg at the later exposure described by the author
Frequency
Monday, Wednesday and Friday at that later exposure
Route
Injection; specific route not stated
Duration
Not specified clearly

Other exposures described: SS-31; MOTS-c

The effects of the products and timing cannot be separated. This does not verify improved NAD levels, mitochondrial repair or safety.

Read the original account
Negative account · adverse event report

Severe chills, shaking, vomiting and fatigue

FDA received these reports after injectable NAD+ products, with some people requiring medical treatment.

Reported use in this account

Product
Compounded injectable NAD+ products in FDA adverse-event reports
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Injection; individual routes not specified in the adverse-event summary
Duration
Not specified clearly

Other exposures described: Possible contamination or excessive endotoxin exposure described by FDA

FDA described reactions consistent with excessive endotoxin exposure. These reports concern compounded sterile products, not a measured rate of intrinsic NAD+ toxicity.

Read the FDA adverse-event communication

Approval status

The linked FDA communication is a compounding safety warning, not an approval decision. The scoped record below documents this limited search; it should not be read as an exhaustive inventory of drug applications or jurisdictions.

Selected sources do not establish a wellness drug-approval pathway

NAD+ is biologically essential, but references do not support an FDA-approved anti-aging, energy, cognition, or addiction-recovery drug use for NAD+ products.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether NAD+ itself produces durable clinical benefits in any wellness population
  • Which route, formulation, or population could justify controlled outcomes trials
  • Long-term safety of repeated exposure
  • Whether changes in NAD-related biomarkers translate into better function or health

Summary

NAD+ biology does not establish wellness-infusion benefits. Clinical outcome evidence is limited, and compounded products add quality risks.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedSystematic review of NAD-related anti-aging interventions

    Review finding no eligible clinical outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.

  2. fdaFDA: reminder about ingredients used in sterile compounding

    FDA warning describing adverse-event reports and quality concerns involving compounded NAD+ products.

  3. pubmedPilot pharmacokinetic study of an NAD+ infusion

    Small study of plasma and urine metabolites that did not test meaningful clinical efficacy.

  4. pubmedRetrospective commercial-clinic NAD+ infusion study

    Nonrandomized safety and tolerability report that cannot establish benefit.

How we assess sources · Suggest a correction